StocksMedium•16 November 2026•
1 min read
Yarrow Bioscience Closes $172.5 Million Public Offering
Key Facts
1Yarrow Bioscience announced the closing of an underwritten public offering of its common stock totaling $172.5 million.
2The company is currently in the process of a merger with VYNE Therapeutics, Inc.
Yarrow Bioscience announced the closing of an underwritten public offering of its common stock totaling $172.5 million. Benzinga reported that the company is currently in the process of a merger with VYNE Therapeutics, Inc., with the offering providing capital as the transaction proceeds.
YARW closed at $18.03 on November 13, 2026, after reaching a day high of $19.86 and a low of $17.99. The finalization of this public offering confirms previous dilution expectations while securing liquidity for the firm's corporate milestones.